… to select more patients likely to benefit. Recent reports note activity with immunotherapies
such as CD40 agonists, CCR2 inhibitors, cancer … the heterogeneity within pancreatic cancers. …

… bias and exact treatment selection process, this study offers … in the therapy of pancreatic
cancer. Although these conclusions … to drive the selection of chemotherapy for pancreatic cancer. …

… Focusing on these criteria, we suggest a step-by-step approach for patients with pancreatic
cancer; the first step is to consider their clinical and laboratory factors and then their …

… , and further explore the novel approaches to metastatic pancreatic cancer, including nal-IRI.
We will discuss the value of using this drug, associated toxicities, and clinical outcomes. …

… of targeted therapies in pancreatic cancer is … pancreatic cancer. Therefore, this review aims
to offer an updated perspective on biomarkers with therapeutic potential in pancreatic cancer. …

… the pharmacogenetic studies will allow the selection of more effective drugs. However,
the … selected on the basis of standard criteria versus treatment selection based on patient/cancer …

… expected frequency for pancreatic cancer, suggesting that these carcinomas are representative
of pancreatic cancer as a whole. In contrast, the expression of a selected group of genes …

… the aggressive behavior of pancreatic cancer and influence response … pancreas cancer
chemotherapy relies on the identification of molecular markers that help in the selection of drugs …

… drug combinations will be selected based on biomarkers, and strategies for pancreatic cancer
… We review the major advances in pancreatic cancer therapy during the last 5 years, and …

… a selected group of pancreatic cancers deficient in the FANC/BRCA pathway. Theoretically,
this approach would prove to be less systemically toxic than traditional chemotherapy, and at …